Aquestive CRL from FDA ‘clearing event,’ says Oppenheimer

Oppenheimer views the complete response letter from the FDA as a “clearing event” for Aquestive Therapeutics (AQST). The letter “provides assurance that the additional work is not related to major concerns to Anaphylm,” the analyst tells investors in a research note. The firm views the keys risk going forward as timeline-driven. It keeps an Outperform rating on Aquestive. The stock in morning trading is up 47%, or $1.39, to $4.34.